523 related articles for article (PubMed ID: 22158905)
1. Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors.
Marshall NA; Galvin KC; Corcoran AM; Boon L; Higgs R; Mills KH
Cancer Res; 2012 Feb; 72(3):581-91. PubMed ID: 22158905
[TBL] [Abstract][Full Text] [Related]
2. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
Hill HC; Conway TF; Sabel MS; Jong YS; Mathiowitz E; Bankert RB; Egilmez NK
Cancer Res; 2002 Dec; 62(24):7254-63. PubMed ID: 12499267
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination.
Pan J; Heiser A; Marget M; Steinmann J; Kabelitz D
Gene Ther; 2005 May; 12(9):742-50. PubMed ID: 15729371
[TBL] [Abstract][Full Text] [Related]
5. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
Zhang W; He L; Cao X
Zhonghua Yi Xue Za Zhi; 1999 Mar; 79(3):170-3. PubMed ID: 11601032
[TBL] [Abstract][Full Text] [Related]
6. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
7. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
[TBL] [Abstract][Full Text] [Related]
9. Microenvironment-derived IL-1 and IL-17 interact in the control of lung metastasis.
Carmi Y; Rinott G; Dotan S; Elkabets M; Rider P; Voronov E; Apte RN
J Immunol; 2011 Mar; 186(6):3462-71. PubMed ID: 21300825
[TBL] [Abstract][Full Text] [Related]
10. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
11. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy with interleukin-10 receptor and interleukin-12 induces a protective interferon-γ-dependent response against B16F10-Nex2 melanoma.
Marchi LH; Paschoalin T; Travassos LR; Rodrigues EG
Cancer Gene Ther; 2011 Feb; 18(2):110-22. PubMed ID: 20885448
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15.
Gri G; Chiodoni C; Gallo E; Stoppacciaro A; Liew FY; Colombo MP
Cancer Res; 2002 Aug; 62(15):4390-7. PubMed ID: 12154045
[TBL] [Abstract][Full Text] [Related]
14. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10.
de Melo FM; Braga CJ; Pereira FV; Maricato JT; Origassa CS; Souza MF; Melo AC; Silva P; Tomaz SL; Gimenes KP; Scutti JA; Juliano MA; Zamboni DS; Câmara NO; Travassos LR; Ferreira LC; Rodrigues EG
Immunol Cell Biol; 2015 Jan; 93(1):86-98. PubMed ID: 25223833
[TBL] [Abstract][Full Text] [Related]
15. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis.
Stagg J; Divisekera U; Duret H; Sparwasser T; Teng MW; Darcy PK; Smyth MJ
Cancer Res; 2011 Apr; 71(8):2892-900. PubMed ID: 21292811
[TBL] [Abstract][Full Text] [Related]
16. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
17. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines.
Yamaguchi S; Tatsumi T; Takehara T; Sakamori R; Uemura A; Mizushima T; Ohkawa K; Storkus WJ; Hayashi N
Cancer; 2007 Oct; 110(7):1469-77. PubMed ID: 17685394
[TBL] [Abstract][Full Text] [Related]
19. Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells.
Wu S; Wang SQ; Zhang J; Tan XY; Liu JN
Int J Oncol; 2006 Mar; 28(3):731-6. PubMed ID: 16465379
[TBL] [Abstract][Full Text] [Related]
20. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
